Design: Pre-treatment and post-treatment questionnaire given to patients with a diagnosis of recurrent epistaxis. Length of treatment was two months. All patients applied NoBleed as directed in the product insert as the sole treatment of their epistaxis during this period.
| 24 | Total Participants |
| 18 | Total 2nd Response |
| 68% | Total study Completion Rate |
| 79% | Percent of patients with epistaxis pre-treatment |
| 17 | Average number of epistaxis events per month per patient pre-treatment |
| 4 | Average number of epistaxis events per month per patient post-treatment |
| 61% | Percent of patients with complete resolution epistaxis |
| 28% | Percent of patients with partial resolution epistaxis |
| 11% | Percent of patients with no decrease in epistaxis |
| 94% | Percent of patients with decreased severity of epistaxis |
| 82% | Percent of patients with decreased duration of epistaxis episodes |
| 94% | Percent of patients tolerating treatment with NoBleed |
| 88% | Percent of patients who would recommend this product |